

Anti-CD80 (Galiximab), Human IgG1, Lambda Antibody

CATALOG NO.: A2011-50 (50 µg)
A2011-100 (100 µg)

BACKGROUND DESCRIPTION: Galiximab is a primatized mAb which consists of human constant and primate (cynomolgus macaque) variable regions and binds specifically to CD80. CD80 is a surface glycoprotein and a member of the B7 family of co-stimulatory molecules. CD80 antigen regulates T cell activation (through interacting with CD28 or CD152) and is expressed transiently in antigen-presenting cells, T cells and normal B cells, and expressed constitutively on various subtypes of B-cell lymphomas. Galiximab acts to decrease in cell proliferation, inhibition of the constitutively active NF-κB pathway, increase in apoptosis and ADCC against various B-cell lymphoma cell lines. Galiximab affects CD28 and CD152 interactions with CD80.

ALTERNATE NAMES: B7-1; T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7

ANTIBODY TYPE: Monoclonal

CLONE: IDEC-114 (Galiximab)

HOST/ISOTYPE: Recombinant / Human IgG1, lambda

IMMUNOGEN: Galiximab was prepared by immunizing cynomolgus monkeys with recombinant CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line

SOURCE: CHO cells

FORM: Liquid

FORMULATION: Supplied in PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Aliquot and store at -20 °C to -80 °C. Avoid repeated freeze-thaw cycles

APPLICATIONS AND USAGE: WB, ELISA, IP, IF, IHC, FC, Block, Modulate

Note: This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-CD52 (Campath-1H), Human IgG1 Antibody (A1105)
 Anti-CD40L (Ruplizumab), Human IgG1 Antibody (A1094)
 Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

FOR RESEARCH USE ONLY! Not to be used on humans.